학술논문

Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma
Document Type
Journal
Source
BRITISH JOURNAL OF HAEMATOLOGY; DEC 20 2020, 9p.
Subject
Language
English
ISSN
13652141